GLP-1 Market
LLY $1416.54 ▲ +3.1% NVO $40.01 ▲ +2.2% PFE $30.50 ▲ +1.9% VKTX $27.30 ▲ +1.6% KLRA $12.86 ▼ -4.1% GPCR $21.87 ▼ -0.3% RHHBY $61.30 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

APX3330

APX3330

Company
Opus Genetics, Inc
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 31, 2026

Trial details
  • Completed NCT NCT03375086

    A Study of APX3330 in Patients With Advanced Solid Tumors

    Not yet reported Apexian Pharmaceuticals, Inc. 19 participants Est. completion 2019-01-09 3 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT04692688

    Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

    Not yet reported Opus Genetics, Inc 103 participants Est. completion 2023-01-25 24 sites Stand-alone
    Other conditions: Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.